Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Tom Vink"'
Autor:
Mario Losen, Aran F. Labrijn, Vivianne H. van Kranen-Mastenbroek, Maarten L. Janmaat, Krista G. Haanstra, Frank J. Beurskens, Tom Vink, Margreet Jonker, Bert A. ‘t Hart, Marina Mané-Damas, Peter C. Molenaar, Pilar Martinez-Martinez, Eline van der Esch, Janine Schuurman, Marc H. de Baets, Paul W. H. I. Parren
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Autoantibodies against ion channels are the cause of numerous neurologic autoimmune disorders. Frequently, such pathogenic autoantibodies have a restricted epitope-specificity. In such cases, competing antibody formats devoid of pathogenic e
Externí odkaz:
https://doaj.org/article/24f5b6bf021946909f7c67a223ec548b
Autor:
Paul W.H.I. Parren, David Miao, Richard Wubbolts, David Satijn, Esther C.W. Breij, Hendrik ten Napel, Tom Vink, Bart E.C.G. de Goeij
Schematic overview of the mechanism of action of bsHER2xCD63his-ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bbcdb01d2ccc5fb6b610c22894bb8f
https://doi.org/10.1158/1535-7163.22506576
https://doi.org/10.1158/1535-7163.22506576
Autor:
Paul W.H.I. Parren, David Miao, Richard Wubbolts, David Satijn, Esther C.W. Breij, Hendrik ten Napel, Tom Vink, Bart E.C.G. de Goeij
Supplementary Figure legends for figures S1, S2 and S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::891230aa29d0679016467a2484f66dcb
https://doi.org/10.1158/1535-7163.22506573.v1
https://doi.org/10.1158/1535-7163.22506573.v1
Data from Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Autor:
Paul W.H.I. Parren, David Miao, Richard Wubbolts, David Satijn, Esther C.W. Breij, Hendrik ten Napel, Tom Vink, Bart E.C.G. de Goeij
Antibody–drug conjugates (ADC) are designed to be stable in circulation and to release potent cytotoxic drugs intracellularly following antigen-specific binding, uptake, and degradation in tumor cells. Efficient internalization and routing to lysos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b52d6e2beb81895041ffd3a36f43115
https://doi.org/10.1158/1535-7163.c.6538437.v1
https://doi.org/10.1158/1535-7163.c.6538437.v1
Autor:
Paul W. H. I. Parren, Tom Vink, Frank J. Beurskens, Marc H. De Baets, Maarten L. Janmaat, Eline van der Esch, Vivianne van Kranen-Mastenbroek, Margreet Jonker, Bert A. 't Hart, Marina Mané-Damas, Aran F. Labrijn, Pilar Martinez-Martinez, Krista G. Haanstra, Janine Schuurman, Mario Losen, Peter C. M. Molenaar
Publikováno v:
Scientific Reports, 7:992. Nature Publishing Group
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Scientific Reports
Autoantibodies against ion channels are the cause of numerous neurologic autoimmune disorders. Frequently, such pathogenic autoantibodies have a restricted epitope-specificity. In such cases, competing antibody formats devoid of pathogenic effector f
Autor:
Simone de Haij, Kristin Strumane, Wim K. Bleeker, Edward Van Den Brink, Matthias Peipp, Bart De Goeij, Tom Vink, Christian Kellner, Rob N. de Jong, Thilo Riedl, Paul W. H. I. Parren
Publikováno v:
mAbs. 6:392-402
The human epidermal growth factor receptor (HER)2 provides an excellent target for selective delivery of cytotoxic drugs to tumor cells by antibody-drug conjugates (ADC) as has been clinically validated by ado-trastuzumab emtansine (Kadcyla(TM)). Whi
Publikováno v:
Methods. 65:5-10
Transient expression systems in mammalian cells have become the method of choice for producing research quantities of antibodies. Both the speed and yield of the available transient systems and the natural posttranslational modifications favor these
Autor:
Paul W. H. I. Parren, Marleen Voorhorst, Patrick J. Engelberts, Tom Vink, Frank J. Beurskens, Thomas Valerius, Wendy J.M. Mackus, Joost M. Bakker, Stefanie Derer, Tom van Meerten, Esther C.W. Breij, Janine Schuurman, Jan G. J. van de Winkel
Publikováno v:
Engelberts, P J, Voorhorst, M, Schuurman, J, Van Meerten, T, Bakker, J M, Vink, T, Mackus, W J M, Breij, E C W, Derer, S, Valerius, T, van de Winkel, J G J, Parren, P W H I & Beurskens, F J 2016, ' Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells ', Journal of Immunology, vol. 197, no. 12, pp. 4829-4837 . https://doi.org/10.4049/jimmunol.1600811
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS
Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab')2 fragments,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d9197ec28f899d5e6a016465f31efa
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381
Autor:
Paul W. H. I. Parren, Antonio Ortiz Buijsse, Wim K. Bleeker, Sandra Verploegen, Jeanette H. W. Leusen, Tom Vink, Marije B. Overdijk
Publikováno v:
The Journal of Immunology. 189:3430-3438
Development of human therapeutic Abs has led to reduced immunogenicity and optimal interactions with the human immune system in patients. Humanization had as a consequence that efficacy studies performed in mouse models, which represent a crucial ste
Autor:
Paul W. H. I. Parren, Tom Vink, Jan G. J. van de Winkel, Patrick Van Berkel, Jesper Valbjørn, Gerrard J. Perdok, Jolanda Gerritsen
Publikováno v:
Biotechnology Progress. 25:244-251
We studied the variations in N-linked glycosylation of human IgG molecules derived from 105 different stable cell lines each expressing one of the six different antibodies. Antibody expression was based on glutamine synthetase selection technology in